Aurobindo Pharma Share Price
- Advice
- Hold
Start SIP in Aurobindo Pharma
Start SIPAurobindo Pharma Performance
Day Range
- Low 1,394
- High 1,410
52 Week Range
- Low 835
- High 1,592
- Open Price1,407
- Previous Close1,397
- Volume39844
Aurobindo Pharma F&O
Aurobindo Pharma Investment Rating
-
Master Rating:
-
Aurobindo Pharma has an operating revenue of Rs. 29,718.37 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 15% is great, ROE of 10% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 69 which is a FAIR score but needs to improve its earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 2,460 | 2,894 | 2,664 | 2,648 | 2,364 | 3,484 |
Operating Expenses Qtr Cr | 1,961 | 2,119 | 2,210 | 2,124 | 1,968 | 2,856 |
Operating Profit Qtr Cr | 499 | 775 | 482 | 545 | 422 | 692 |
Depreciation Qtr Cr | 67 | 65 | 64 | 66 | 60 | 115 |
Interest Qtr Cr | 51 | 53 | 61 | 37 | 32 | 49 |
Tax Qtr Cr | 117 | 201 | 63 | 130 | 90 | 171 |
Net Profit Qtr Cr | 329 | 579 | 624 | 416 | 336 | 645 |
Aurobindo Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 3
- Bearish Moving Average
- ___
- 13
- 20 Day
- ₹1,445.35
- 50 Day
- ₹1,458.71
- 100 Day
- ₹1,409.50
- 200 Day
- ₹1,287.91
- 20 Day
- ₹1,454.16
- 50 Day
- ₹1,497.09
- 100 Day
- ₹1,423.36
- 200 Day
- ₹1,265.49
Aurobindo Pharma Resistance and Support
Resistance | |
---|---|
First Resistance | 1,409.13 |
Second Resistance | 1,417.57 |
Third Resistance | 1,425.13 |
RSI | 34.02 |
MFI | 10.79 |
MACD Single Line | -18.39 |
MACD | -24.13 |
Support | |
---|---|
First Support | 1,393.13 |
Second Support | 1,385.57 |
Third Supoort | 1,377.13 |
Aurobindo Pharma Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 41,408 | 1,393,379 | 33.65 |
Week | 643,573 | 33,118,287 | 51.46 |
1 Month | 751,566 | 35,849,698 | 47.7 |
6 Month | 1,419,012 | 68,864,638 | 48.53 |
Aurobindo Pharma Result Highlights
Aurobindo Pharma Synopsis
NSE-Medical-Generic Drugs
Aurobindo Pharma Ltd. is a leading integrated global pharmaceutical company . Initially specializing in Semi-Synthetic Penicillins, the company has expanded its product portfolio to include a wide range of therapeutic areas such as neurosciences, cardiovascular, anti-retrovirals, gastroenterology, and antibiotics. Aurobindo Pharma operates 25 manufacturing and packaging facilities approved by major regulatory bodies like the USFDA and UK MHRA, and it distributes its products in over 150 countries. The company's growth is supported by robust R&D capabilities and a strong commitment to operational excellence.Market Cap | 81,109 |
Sales | 10,715 |
Shares in Float | 27.88 |
No of funds | 745 |
Yield | 0.32 |
Book Value | 4.15 |
U/D Vol ratio | 0.8 |
LTDebt / Equity | |
Alpha | 0.14 |
Beta | 0.63 |
Aurobindo Pharma Shareholding Pattern
Owner Name | Sep-24 | Jun-24 | Mar-24 | Dec-23 |
---|---|---|---|---|
Promoters | 51.82% | 51.8% | 51.83% | 51.83% |
Mutual Funds | 18.53% | 19.17% | 17.83% | 14.7% |
Insurance Companies | 4.66% | 5.19% | 5.03% | 5.53% |
Foreign Portfolio Investors | 16.59% | 16.73% | 18.01% | 20.72% |
Financial Institutions/ Banks | 0.07% | |||
Individual Investors | 5.33% | 5.47% | 5.51% | 5.65% |
Others | 3% | 1.64% | 1.79% | 1.57% |
Aurobindo Pharma Management
Name | Designation |
---|---|
Mr. M Ramasubramanian Kumar | Chairman & Ind.Dire (Non-Exe) |
Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
Mr. M Madan Mohan Reddy | Whole Time Director |
Mr. P V Ramprasad Reddy | Non Executive Director |
Dr. Satakarni Makkapati | Non Executive Director |
Mr. P Sarath Chandra Reddy | Non Executive Director |
Mr. Girish P Vanvari | Independent Director |
Mrs. Savita Mahajan | Independent Director |
Mr. Santanu Mukherjee | Independent Director |
Dr. Deepali Pant Joshi | Independent Director |
Aurobindo Pharma Forecast
Price Estimates
Aurobindo Pharma Corporate Action
Date | Purpose | Remarks |
---|---|---|
2024-08-10 | Quarterly Results | |
2024-07-18 | Buy Back of Shares | To consider buyback for equity shares per share(125%)Interim Dividend |
2024-05-25 | Audited Results | |
2024-02-10 | Quarterly Results & Interim Dividend | |
2023-11-09 | Quarterly Results & Interim Dividend |
Date | Purpose | Remarks |
---|---|---|
2024-02-20 | INTERIM | Rs.1.50 per share(150%)Second Interim Dividend |
2023-11-20 | INTERIM | Rs.3.00 per share(300%)First Interim Dividend |
2023-02-17 | INTERIM | Rs.3.00 per share(300%)Interim Dividend |
2022-06-07 | INTERIM | Rs.4.50 per share (450%) Fourth Interim Dividend |
2022-02-21 | INTERIM | Rs.1.50 per share(150%)Third Interim Dividend |
Aurobindo Pharma FAQs
What is Share Price of Aurobindo Pharma ?
Aurobindo Pharma share price is ₹1,400 As on 03 November, 2024 | 18:19
What is the Market Cap of Aurobindo Pharma ?
The Market Cap of Aurobindo Pharma is ₹81352.9 Cr As on 03 November, 2024 | 18:19
What is the P/E ratio of Aurobindo Pharma ?
The P/E ratio of Aurobindo Pharma is 23.1 As on 03 November, 2024 | 18:19
What is the PB ratio of Aurobindo Pharma ?
The PB ratio of Aurobindo Pharma is 2.7 As on 03 November, 2024 | 18:19
Is it a good time to invest in Aurobindo Pharma?
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
How many times have Aurobindo Pharma given dividends since 2000?
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
What is the stock price CAGR of Aurobindo Pharma?
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
What is the ROE of Aurobindo Pharma?
Aurobindo Pharma has an ROE of 24% which is exceptional.
What is Aurobindo Pharma’s debt to equity?
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.